TOP2A and neoplasm: In addition, tumor cells with p53 mutations may exhibit high levels of TOP2A and may be more sensitive to TOP2A inhibitors (Liu et al., 2002); about 90% of patients with SCLC have p53 mutations (Delgado et al., 2005).